Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2019 07:03 ET | Source: Aptinyx Inc.

Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
September 26, 2019 08:07 ET | Source: Aptinyx Inc.

Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925

EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
September 04, 2019 07:27 ET | Source: Aptinyx Inc.

Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors

EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
August 21, 2019 08:33 ET | Source: Aptinyx Inc.

Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury

EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
August 12, 2019 06:33 ET | Source: Aptinyx Inc.

Aptinyx Reports Second Quarter 2019 Financial Results and Highlights

Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
August 06, 2019 08:33 ET | Source: Aptinyx Inc.

Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference

EVANSTON, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
August 05, 2019 08:03 ET | Source: Aptinyx Inc.

Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019

EVANSTON, Ill., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
July 12, 2019 08:30 ET | Source: Aptinyx Inc.

Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal

EVANSTON, Ill., July 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
June 26, 2019 08:03 ET | Source: Aptinyx Inc.

Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder

EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
June 18, 2019 08:27 ET | Source: Aptinyx Inc.

Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference

EVANSTON, Ill., June 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right